ES2527010T3 - Complejo de flurano - Google Patents

Complejo de flurano Download PDF

Info

Publication number
ES2527010T3
ES2527010T3 ES11700182.6T ES11700182T ES2527010T3 ES 2527010 T3 ES2527010 T3 ES 2527010T3 ES 11700182 T ES11700182 T ES 11700182T ES 2527010 T3 ES2527010 T3 ES 2527010T3
Authority
ES
Spain
Prior art keywords
flurane
complex
flurane complex
weight
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11700182.6T
Other languages
English (en)
Inventor
Norbert Roewer
Jens Broscheit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapiotec GmbH
Original Assignee
Sapiotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapiotec GmbH filed Critical Sapiotec GmbH
Application granted granted Critical
Publication of ES2527010T3 publication Critical patent/ES2527010T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Complejo compuesto de α-ciclodextrina y un flurano, caracterizado por un contenido de flurano de al menos el 3 % en peso en el peso total del complejo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11700182.6T 2010-01-14 2011-01-14 Complejo de flurano Active ES2527010T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10150786 2010-01-14
EP20100150786 EP2345427A1 (de) 2010-01-14 2010-01-14 Flurankomplex
PCT/EP2011/050428 WO2011086146A1 (de) 2010-01-14 2011-01-14 Flurankomplex

Publications (1)

Publication Number Publication Date
ES2527010T3 true ES2527010T3 (es) 2015-01-19

Family

ID=42145043

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11700182.6T Active ES2527010T3 (es) 2010-01-14 2011-01-14 Complejo de flurano

Country Status (16)

Country Link
US (1) US9125953B2 (es)
EP (2) EP2345427A1 (es)
JP (1) JP5752710B2 (es)
KR (1) KR101767283B1 (es)
CN (1) CN102933235B (es)
CA (1) CA2787115C (es)
CY (1) CY1115967T1 (es)
DK (1) DK2523691T3 (es)
ES (1) ES2527010T3 (es)
HR (1) HRP20141273T1 (es)
PL (1) PL2523691T3 (es)
PT (1) PT2523691E (es)
RS (1) RS53714B1 (es)
SI (1) SI2523691T1 (es)
SM (1) SMT201400194B (es)
WO (1) WO2011086146A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102147084B1 (ko) 2012-11-15 2020-08-24 자피오텍 게엠베하 소염성 활성 물질 또는 면역 억제성 활성물질로서 델피니딘 복합제
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
EP2913050A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
CN209194072U (zh) * 2015-06-30 2019-08-02 珀金埃尔默健康科学股份有限公司 气相色谱系统
CN112218529A (zh) * 2018-04-27 2021-01-12 福莱西因赛特股份有限公司 包含1-甲基环丙烯与α-环糊精的络合物的组合物和制品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3216897A (en) * 1961-11-02 1965-11-09 Air Reduction Injectable anesthetic
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
CN1116031C (zh) * 1999-08-17 2003-07-30 刘进 静脉注射用乳化吸入全身麻醉药及其制备方法
IN187686B (es) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
CN1424112A (zh) * 2002-12-17 2003-06-18 上海医药工业研究院 难溶性药物的水溶性包合物及其制备方法
EP2099408B1 (en) * 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
US20110159078A1 (en) * 2008-01-22 2011-06-30 Vapogenix, Inc Volatile Anesthetic Compositions and Methods of Use

Also Published As

Publication number Publication date
CA2787115A1 (en) 2011-07-21
PL2523691T3 (pl) 2015-03-31
SMT201400194B (it) 2015-03-05
SI2523691T1 (sl) 2015-02-27
HRP20141273T1 (hr) 2015-02-27
PT2523691E (pt) 2015-01-05
EP2523691B1 (de) 2014-10-01
EP2523691A1 (de) 2012-11-21
CN102933235B (zh) 2015-11-25
US9125953B2 (en) 2015-09-08
CY1115967T1 (el) 2017-01-25
KR20120105563A (ko) 2012-09-25
US20120296077A1 (en) 2012-11-22
KR101767283B1 (ko) 2017-08-10
JP2013517254A (ja) 2013-05-16
DK2523691T3 (en) 2015-01-12
CA2787115C (en) 2017-10-24
JP5752710B2 (ja) 2015-07-22
CN102933235A (zh) 2013-02-13
WO2011086146A1 (de) 2011-07-21
RS53714B1 (sr) 2015-04-30
EP2345427A1 (de) 2011-07-20

Similar Documents

Publication Publication Date Title
ES2642212T3 (es) Cierre de cremallera
JP2012525416A5 (es)
JP2011026329A5 (es)
JP2011006413A5 (es)
JP2011093937A5 (es)
JP2013539946A5 (es)
JP2012023335A5 (es)
JP2013531034A5 (es)
JP2012524113A5 (es)
JP2014505137A5 (es)
JP2012031285A5 (es)
MX2019010594A (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
JP2012204203A5 (es)
JP2013064178A5 (es)
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
JP2012011657A5 (es)
JP2010166925A5 (es)
JP2011208181A5 (es)
JP2011207949A5 (es)
JP2012011658A5 (es)
JP2012042569A5 (es)
JP2012190699A5 (es)
ES2527010T3 (es) Complejo de flurano
JP2011233516A5 (es)
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido